QQQ   351.17 (+0.91%)
AAPL   179.71 (+1.39%)
MSFT   330.69 (+0.70%)
META   270.26 (+2.09%)
GOOGL   123.23 (+0.29%)
AMZN   122.67 (+1.73%)
TSLA   204.81 (+0.43%)
NVDA   394.92 (+4.38%)
NIO   7.47 (-0.80%)
BABA   83.04 (+4.39%)
AMD   119.58 (+1.16%)
T   15.82 (+0.57%)
F   12.07 (+0.58%)
MU   69.04 (+1.23%)
CGC   0.85 (+1.21%)
GE   104.72 (+3.14%)
DIS   88.53 (+0.65%)
AMC   4.60 (+2.22%)
PFE   38.08 (+0.16%)
PYPL   62.91 (+1.48%)
NFLX   401.77 (+1.65%)
QQQ   351.17 (+0.91%)
AAPL   179.71 (+1.39%)
MSFT   330.69 (+0.70%)
META   270.26 (+2.09%)
GOOGL   123.23 (+0.29%)
AMZN   122.67 (+1.73%)
TSLA   204.81 (+0.43%)
NVDA   394.92 (+4.38%)
NIO   7.47 (-0.80%)
BABA   83.04 (+4.39%)
AMD   119.58 (+1.16%)
T   15.82 (+0.57%)
F   12.07 (+0.58%)
MU   69.04 (+1.23%)
CGC   0.85 (+1.21%)
GE   104.72 (+3.14%)
DIS   88.53 (+0.65%)
AMC   4.60 (+2.22%)
PFE   38.08 (+0.16%)
PYPL   62.91 (+1.48%)
NFLX   401.77 (+1.65%)
QQQ   351.17 (+0.91%)
AAPL   179.71 (+1.39%)
MSFT   330.69 (+0.70%)
META   270.26 (+2.09%)
GOOGL   123.23 (+0.29%)
AMZN   122.67 (+1.73%)
TSLA   204.81 (+0.43%)
NVDA   394.92 (+4.38%)
NIO   7.47 (-0.80%)
BABA   83.04 (+4.39%)
AMD   119.58 (+1.16%)
T   15.82 (+0.57%)
F   12.07 (+0.58%)
MU   69.04 (+1.23%)
CGC   0.85 (+1.21%)
GE   104.72 (+3.14%)
DIS   88.53 (+0.65%)
AMC   4.60 (+2.22%)
PFE   38.08 (+0.16%)
PYPL   62.91 (+1.48%)
NFLX   401.77 (+1.65%)
QQQ   351.17 (+0.91%)
AAPL   179.71 (+1.39%)
MSFT   330.69 (+0.70%)
META   270.26 (+2.09%)
GOOGL   123.23 (+0.29%)
AMZN   122.67 (+1.73%)
TSLA   204.81 (+0.43%)
NVDA   394.92 (+4.38%)
NIO   7.47 (-0.80%)
BABA   83.04 (+4.39%)
AMD   119.58 (+1.16%)
T   15.82 (+0.57%)
F   12.07 (+0.58%)
MU   69.04 (+1.23%)
CGC   0.85 (+1.21%)
GE   104.72 (+3.14%)
DIS   88.53 (+0.65%)
AMC   4.60 (+2.22%)
PFE   38.08 (+0.16%)
PYPL   62.91 (+1.48%)
NFLX   401.77 (+1.65%)
NASDAQ:STRO

Sutro Biopharma (STRO) Stock Forecast, Price & News

$4.50
+0.01 (+0.22%)
(As of 11:57 AM ET)
Compare
Today's Range
$4.34
$4.53
50-Day Range
$4.25
$5.88
52-Week Range
$3.33
$8.72
Volume
84,433 shs
Average Volume
482,007 shs
Market Capitalization
$270.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Sutro Biopharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
285.2% Upside
$17.33 Price Target
Short Interest
Bearish
5.15% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.22mentions of Sutro Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.87) to ($2.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

1027th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

159th out of 330 stocks


STRO stock logo

About Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

AI Getting Close to Thinking Like Humans
Technology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
JMP Securities Reaffirms Their Buy Rating on Sutro Biopharma (STRO)
STRO Sutro Biopharma, Inc.
Where Sutro Biopharma Stands With Analysts
See More Headlines

STRO Price History

STRO Company Calendar

Last Earnings
11/10/2021
Today
6/01/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.33
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+286.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-119,200,000.00
Net Margins
-174.57%
Pretax Margin
-170.69%

Debt

Sales & Book Value

Annual Sales
$67.77 million
Book Value
$3.08 per share

Miscellaneous

Free Float
55,738,000
Market Cap
$270.25 million
Optionable
Not Optionable
Beta
0.88

Key Executives

  • William J. Newell
    President, Chief Executive Officer & Director
  • Edward C. Albini
    Chief Financial Officer & Secretary
  • Trevor Hallam
    Chief Scientific Officer & President-Research
  • Shabbir T. Anik
    Chief Technical Operations Officer
  • Craig Berman
    Vice President-Clinical Development













STRO Stock - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price forecast for 2023?

6 Wall Street analysts have issued twelve-month target prices for Sutro Biopharma's stock. Their STRO share price forecasts range from $8.00 to $25.00. On average, they anticipate the company's stock price to reach $17.33 in the next twelve months. This suggests a possible upside of 286.0% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How have STRO shares performed in 2023?

Sutro Biopharma's stock was trading at $8.08 at the start of the year. Since then, STRO shares have decreased by 44.4% and is now trading at $4.49.
View the best growth stocks for 2023 here
.

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our STRO earnings forecast
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.02. The firm earned $8.52 million during the quarter, compared to analysts' expectations of $8.85 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 59.26% and a negative net margin of 174.57%.

What ETFs hold Sutro Biopharma's stock?
What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.45%), BlackRock Inc. (8.34%), Rubric Capital Management LP (7.24%), State Street Corp (4.86%), Candriam S.C.A. (3.09%) and Dimensional Fund Advisors LP (1.95%). Insiders that own company stock include John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends
.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $4.49.

How much money does Sutro Biopharma make?

Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $270.25 million and generates $67.77 million in revenue each year. The company earns $-119,200,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis.

How many employees does Sutro Biopharma have?

The company employs 224 workers across the globe.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.

This page (NASDAQ:STRO) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -